Verified, then logged.
Sun 22 Nov 2026 · 00:22 KST / 15:22 UTC한국어 | ENSearch /

08 / Industry · Analysis

Boltz raises $110 million for AI drug research in a Series A

New and returning investors joined the Bessemer-led round, which Boltz raised to speed up small-molecule research.

Boltz raised $110 million in a Series A, SiliconANGLE reported. Bessemer led the round.

SiliconANGLE linked the raise to Boltz's work on AI for small-molecule research. It described Boltz as a developer of AI models for pharmaceutical researchers.

Boltz said new and returning investors took part, SiliconANGLE reported.

Investors in the Series A

SiliconANGLE named Greycroft and Andreessen Horowitz as investors. Amplify Partners and F-Prime Capital also took part. Hummingbird joined the round as well.

The amount SiliconANGLE reported covered the full round. Its report gave no breakdown by investor or payment dates.

The goal of faster small-molecule research

SiliconANGLE reported that Boltz raised the money to speed up small-molecule research.

The report did not say how much time Boltz aimed to save. It gave no target date for reaching that goal.